India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

Empagliflozin improved clinical outcomes in patients with acute heart failure (AHF), regardless of blood pressure (BP) levels, with particularly strong benefits observed in those with diastolic BP ...

The kind of, molecule, the API when we export is being ... will not be changed but new patients, would be given Empagliflozin. That’s a kind of an assumption we make. On the basis of that ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney risks, holds significant promise for volume growth as it becomes more ...

Earlier this week, German manufacturer Boehringer Ingelheim’s patent to manufacture Empagliflozin, a medication to treat type 2 diabetes mellitus, expired in India. Empagliflozin is sold under ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

We also published positive results from our LEGEND Phase 2 proof-of-concept study evaluating lanifibranor in combination with empagliflozin, which further elucidated the potential of lanifibranor ...

By introducing Empagliflozin at INR 5.49 per tablet for ... API raw material which is DMF grade,” he informed. The kind of, molecule, the API when we export is being used, the same has been ...